Pharmaceuticals

UCB S.A.

QMVentures Successfully Facilitates Candid Therapeutics’ Acquisition by UCB for $2.2B

UCB Forms Multi-Project Strategic Alliance with Cancer Research Institutions for Cancer Therapy Development

Barclays Analyst Maintains Buy Rating on UCB SA

Edding Genor Initiates GB261 Clinical Trials

Candid Therapeutics Terminates Merger Agreement with Rallybio and Signs New Agreement with UCB

UCB Agrees to Acquire Candid Therapeutics for up to $2.2 Billion

UCB Completes Its 2026 Share Repurchase Program

UCB Launches New Gene Therapy Facility in Belgium

UCB Presents New Clinical and Real-World Data at Annual Meeting

UCB stock price jumps, analysts give buy rating

UCB to acquire Neurona Therapeutics for up to $1.15 billion

UCB Announces BIMZELX's BE HEARD Trial Results for Severe Underarm Dermatitis

UCB Presents New Data on BIMZELX for Treating Psoriasis at AAD Annual Meeting

UCB Announces $2 Billion Investment in Georgia for New Biopharmaceutical Production Facility

PANTHERx® Rare Named Exclusive Specialty Pharmacy for KYGEVVI™

TD Cowen Reiterates Buy Rating on UCB SA with a Price Target of €310

Tubize SA Increases UCB Shares and Announces Board Changes

Barclays Analyst Maintains Buy Rating on UCB SA with Target Price of €310

UCB S.A. Obtained Exclusive Rights to Develop and Commercialize ATG-201

UCB S.A. released FY2025 Q4 earnings on February 27 (EST), actual revenue USD 2.498 B, actual EPS USD 1.6417

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

UCBJY

LABU

SBIO

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

United Community Banks

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

UCB has formed a multi-project strategic alliance with Cancer Research UK and Cancer Research Horizons to enhance the development of novel cancer therapies. This collaboration builds on a previous partnership and now includes earlier stage discovery and preclinical programs. UCB will leverage Cancer Research UK's oncology expertise, while both parties will share research and development costs. UCB retains exclusive rights to further develop and commercialize the programs, with Cancer Research Horizons receiving milestone and royalty payments. The alliance aims to accelerate innovative therapeutics for cancer patients.

UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

UCB doubles down on TCEs with $2.2bn Candid buyout

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA, with a price target of €310.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks According to TipRanks, Pitman CFA is ranked #1567 out of 12175 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for UCB SA with a €299.88 average price target.

Tip Ranks

Barclays

Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)

UCB has agreed to acquire Candid Therapeutics for over $2.2 billion, which includes the clinical-stage T-cell engager cizutamig, aimed at treating autoimmune diseases. The deal involves a $2 billion upfront payment and up to $200 million in milestone payments, expected to close by mid-2026, pending regulatory approval. UCB anticipates the acquisition will fit within its financial framework, with revenue growth projected in the high single-digit to low double-digit range. This acquisition aligns with UCB's strategy to enhance its immunology portfolio and expand its T-cell engager capabilities.

Pharmexec

Candel Therapeutics

ANTENGENE-B

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB | AKTS Stock News

StockTitan

AKOUSTIS TECHNOLOGIES INC

United Community Banks, Inc.

UNITED CMNTY BKS INC 6.875% DEP SHS REP 1/1000 NON CU PF SR I

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB | AKTS Stock News

UCB S.A.(UCBJY.US)

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies

UCB doubles down on TCEs with $2.2bn Candid buyout

Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB | AKTS Stock News